Aleafia Health Inc.’s (TSX:ALEF, OTC:ALEAF, FRA: ARAH)) (“Aleafia Health” or the “Company”) wholly owned subsidiary, Emblem Cannabis Corp., has secured two Health Canada licence amendments that expand processing capacity, allowing for the sale of new product formats at its Paris Processing facility. The amendments apply to the licensed and operational Paris location, which processes all of the Company’s extraction, packaging and order fulfilment for Canadian and international sales.
As a result of the licence amendments, the Company is now authorized to produce and sell new product formats and has adequate, licensed production space to do so.
“These licence amendments are well timed, increasing the versatility of our Paris Facility, while ensuring we can move immediately to the production of new cannabis 2.0 formats,” said Aleafia Health CEO Geoffrey Benic. “The additional processing capacity will also allow us to accelerate the production of oil-based products derived from our recent outdoor harvest.”
The first Licence Amendment vastly increases the Company’s ability to produce finished cannabis products by authorizing activities including extraction, packaging and labeling in four rooms that were previously only authorized for cannabis cultivation. The amendment doubles the Paris Facility’s licensed processing space. The second Licence Amendment permits the Company to produce and sell edibles, topicals and extracts to the Canadian market.
PARIS FACILITY PHASE II EXPANSION
Following the issuance of the amended licence and closing of corresponding application, the Company submitted its final Site Evidence Package (“SEP”) to Health Canada for the Phase II expansion of its Paris Processing facility. The final stage in the Company’s licence amendment application for the proposed expansion, the SEP demonstrates that the facility is operational ready and meets all Health Canada requirements.
The Paris Phase II expansion, a 30,000 sq. ft. facility, is entirely dedicated to the extraction, production, packaging and distribution of high-margin, value-added cannabis health and wellness products. The expansion is purpose-built to meet European Union Good Manufacturing Practices (“EU-GMP”) certification requirements. EU-GMP certified facilities demonstrate the highest level of pharmaceutical-grade quality, and securing the certification (along with applicable import and export permits) will allow Aleafia Health to begin exporting medical cannabis products to the European Union market.